Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure
Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.
Advanced/Metastatic Cervical Cancer
DRUG: Cabozantinib
efficacy of cabozantinib: proportion of patients with disease control rate, Efficacy assessed by the proportion of patients with disease control rate, 3 months after cabozantinib treatment initiation.|Safety of cabozantinib: proportion of patients with clinical gastro-intestinal (GI) perforation/fistula, GI-vaginal fistula and genito-urinary (GU) fistula events grade ≥ 2 (NCI CTCAE v 5.0), Safety assessed by the proportion of patients with clinical gastro-intestinal (GI) perforation/fistula, GI-vaginal fistula and genito-urinary (GU) fistula events grade ≥ 2 (NCI CTCAE v 5.0), toxicities occurring up to 1 month after the end of treatment
Objective response (RECIST v1.1 criteria), Objective response rate defined as the percentage of patients who have achieved complete response or partial response with RECIST 1.1 criteria., At the end of cycle 3,6,9... (each cycle is 28 days) through study completion, an average of 1 year|Progression-free survival (PFS), Progression-free survival, defined as the time between initiation of cabozantinib treatment and progression (RECIST 1.1 criteria) or death of any cause whichever occurs first., At the end of cycle 3,6,9... (each cycle is 28 days) through study completion, an average of 1 follow-up year|Overall survival, Overall survival, defined as the time between initiation of cabozantinib treatment and death of whatever cause., through study completion, an average of 1 follow-up year|Safety profile of cabozantinib, Toxicities evaluated according to NCI CTCAE v5.0 criteria, in terms of kind, grade, time of onset, reversibility, every cycle of treatment (each cycle is 28 days) through study completion, an average of 1 follow-up year|Incidence of treatment Quality-of-life of patients assessed by EORTC QLQ-C30 /CX24 questionnaire, Scores of Quality-of-life according to French versions of the self-administered standardized validated questionnaire: EORTC QLQ-C30 with CX24, At Day 15 of cycle 2 (each cycle is 28 days) and every 3 cycles of treatment ((every 12 weeks)) an average of 1 follow-up year
Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.